March 1, 2019

Demetrios Kouzoukas
Principal Deputy Administrator and Director
Center for Medicare

Jennifer Wuggazer Lazio, F.S.A., M.A.A.A.
Director, Parts C & D Actuarial Group
Office of the Actuary

Centers for Medicare and Medicaid Services
United States Department of Health and Human Services
200 Independence Avenue, SW
Washington, DC 20201


Dear Director Kouzoukas and Director Lazio:

The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments in response to the notice titled “Advance Summary of Methodological Changes for Calendar Year (CY) 2020 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2020 Call Letter [CMS-2018-0154]” released on January 30, 2019. AMCP offers comments on the following sections of the notice:

A. Part D Benefit Parameters for Non-Defined Standard Plans
B. Formulary Submissions
C. Medication Therapy Management (MTM)
D. Part D Mail Order Auto-Ship Modifications

AMCP is the nation’s leading professional association dedicated to increasing patient access to affordable medicines, improving health outcomes and ensuring the wise use of healthcare dollars. Through evidence- and value-based strategies and practices, the Academy’s 8,000 pharmacists, physicians, nurses and other practitioners manage medication therapies for the 270 million Americans served by health plans, pharmacy benefit management firms, emerging care models and government.
A. Part D Benefit Parameters for Non-Defined Standard Plans

Improving Access to Generic and Biosimilar Medicines

CMS Commentary
CMS is seeking feedback on whether it should discourage or prohibit Part D plans from including brand and generic drugs on the same tier. Such a policy would require generic drugs to be placed only on generic tiers and brand drugs to be placed only on brand tiers. It would also eliminate the non-preferred drug tier. CMS also seeks feedback on whether it should require Part D plans (PDPs) to automatically place new generic entrants into a generic tier immediately after launch, how biosimilars should be treated under this policy, and whether generics and biosimilars should be allowed on specialty tiers if they meet the specialty threshold.

AMCP Response
AMCP appreciates CMS’s intent to improve generic utilization, lower out-of-pocket costs, and avoid beneficiary confusion. However, AMCP has concerns with several of the areas regarding tier composition for generic and biosimilar medications where CMS is seeking feedback. AMCP supports flexibly for PDPs to establish evidence-based formularies to manage high-cost medications, especially given that high cost generic medications are becoming increasingly more common. CMS’s proposal to discourage or prohibit PDPs from including brand and generic drugs on the same tier would remove plan flexibility to manage high cost generic medications. This could inadvertently result in higher out-of-pocket costs for all generics and/or less choice for beneficiaries. As such, AMCP does not recommend that CMS consider requiring or recommending this alternative policy.

Additionally, AMCP does not support automatic inclusion of newly available generics on generic tiers as there is little cost-relief to brand pricing with first-to-market generics. PDPs should have the flexibility to place newly approved generics in Tiers 3 – 5 and move to generic tiers when pricing is appropriate. Furthermore, PDPs should be allowed to use existing Pharmacy and Therapeutics Committees (P&T Committees) to determine tier placement of generic medications. Moreover, PDPs should be able to place any drug that meets the specialty drug cost threshold in a specialty tier, regardless with whether it is a brand, generic, or biosimilar. Lastly, AMCP does not believe that biosimilars should be treated the same as generic medications in terms of specialty tier placement. Generic medications can cost, on average, 80 to 85 percent less than the brand-name equivalents\(^1\) while biosimilars are estimated to produce discounts of 20-40% from the cost of the originator biologic.\(^2\) Given this difference, biologics that enter the market do not produce the same level of cost offsets as compared to small molecule generic products and therefore, CMS should be mindful that

---


plans must consider the additional costs of biosimilars when developing formularies. Moreover, classifying biosimilars as generics with generic co-pays would eliminate incentives for manufacturers to offer their formulations at a significantly lower price than the originator biologic.

B. Formulary Submissions

*Naloxone Co-Prescribing*

**CMS Proposal**

CMS is encouraging the co-prescribing of naloxone with opioid prescriptions to beneficiaries who are at increased risk for opioid overdose consistent with guidance from the Centers for Disease Control and Prevention (CDC) and the Department of Health and Human Services (HHS). CMS is also recommending targeted education of prescribers and enrollees on co-prescribing of naloxone to prevent accidental overdoses.

**AMCP Recommendations**

AMCP is committed to resolving issues associated with the opioid epidemic and established an Addiction Treatment Advisory Group (ATAG) in 2016 to evaluate current gaps and barriers to addiction treatment services and develop initial recommendations to improve access to addiction treatment. The recommendations outlined issues and barriers to receiving timely naloxone therapy, shared best practices within managed care, and highlighted opportunities for managed care to impact these complex issues. Two specific examples of opportunities for managed care organizations to improve access to naloxone and support patients with substance use disorder outlined by the ATAG that are specific to co-prescribing include:

- Develop quality improvement or management strategies that mitigate the risk of overdose through co-prescribing of naloxone when factors that could increase the risk of overdose are present (e.g., history of substance use disorder, opioid dosages over 50 MME/day and/or current benzodiazepine use); and
- Promote the use of naloxone and co-prescribing through provider guidelines or education, in member educational trainings or materials, and through formulary placement.

AMCP supports increased accessibility to, and affordability of, naloxone and other rescue drugs for patients. While there has been progress in improving general naloxone access, there is also opportunity to continue to improve access for at-risk individuals. To that effect, we appreciate

---


CMS’s proposal to encourage the co-prescribing of naloxone with opioid prescriptions to beneficiaries at increased-risk for opioid overdose. However, is it equally important to ensure that the co-prescribing of naloxone is targeting the most appropriate population of beneficiaries through the use of quality improvement or management strategies.

AMCP recommends that CMS work with other stakeholders to establish evidence-based criteria for co-prescribing of naloxone. The AMCP Addiction Advisory Group (AAG), established in March 2018, will continue AMCP's ongoing efforts to promote best practices that improve addiction prevention and treatment services such as naloxone co-prescribing. The AAG is currently working on developing recommendations for the role of managed care pharmacy in co-prescribing naloxone for patients with specific risk. AMCP will share the recommendations and findings from the advisory group with CMS once finalized.

C. Medication Therapy Management

Comprehensive Medication Review Summary Standardized Format

CMS Commentary
CMS recently gathered feedback from consumers and other stakeholders on what improvements could be made to the Medicare Part D Program Medication Therapy Management (MTM) Standardized Format (“standardized format”) which is a written summary of a comprehensive medication review (CMR) that must be offered annually for targeted beneficiaries. As a result of this feedback, CMS will propose revisions to the standardized format for public comment with the goal of optimizing the utility of the CMR summary for beneficiaries.

AMCP Response
AMCP appreciates the opportunity to provide comments and feedback to CMS on how to improve the delivery of MTM. Previously, AMCP submitted comments in response to “CMS-10396 Medication Therapy Management Program Improvements” published in the Federal Register on October 31, 2016. In those comments, AMCP urged CMS to work with the pharmacy profession to modernize, test, and validate alternate formats to maximize its intended benefit for Medicare beneficiaries and to work towards implementing a new standardized format in advance of 2020.5

AMCP created the Medication Therapy Management Advisory Group (MTMAG) in 2015 to advise AMCP staff on critical issues in the delivery of MTM related services and provide practical recommendations for MTM practice and administration. The MTMAG is comprised of 40+ MTM stakeholders, including AMCP members and non-members who represent Medicare Part D sponsors, MTM vendors, technology vendors, community MTM providers, pharmacy professional organizations, EHR vendors, integrated delivery networks, and academia. One of the key goals

identified by the MTMAG is to evaluate how the current MTM standardized format can be modernized to maximize its intended benefit for Medicare beneficiaries.

Recent AMCP research focused on the utilization of the standardized format among beneficiaries has brought to light several areas for improvement in the standardized format document. MTMAG members were instrumental in disseminating and collecting information from beneficiaries for this study. The research findings suggest that beneficiary focused modifications could result in improved use of the standardized format and ultimately improve the MTM benefit. Publication of this research in the Journal of Managed Care and Specialty Pharmacy (JMCP) is now available and a poster of the research will be presented at the AMCP Annual Meeting, March 25 – 28, 2019. AMCP looks forward to sharing recommendations from this research in CMS’s future proposal to help influence improvements to the standardized format.

As CMS seeks to improve the value of the CMR for beneficiaries and reduce burden on Part D sponsors, MTMAG members advised AMCP to recommend that CMS provide clear recommendations on how to conduct a CMR in circumstances where a beneficiary is unable to directly participate in the service. As defined in the annual call letter and 42 CFR §423.153(d), the CMR must include “…an interactive, person-to-person, or telehealth medication review and consultation of the beneficiary’s medications…” and “Sponsors should maintain documentation regarding the delivery of CMRs including who performed the CMR, who received the CMR, and when the CMR was delivered.” A CMR prevents adverse drug events, improves medication adherence, increases beneficiary self-management of their chronic illness, and helps ensure optimal treatment outcomes.

AMCP appreciates the focus CMS has placed on the CMR and the CMR completion rate. We note that, unfortunately, a beneficiary may be “unable to participate” in a CMR for various reasons which may include cognitive impairment, health literacy, language barrier, access to services, or access to technology. These reasons are also often aligned with social determinants of health. Fortunately, CMS permits the CMR to be performed with “…the patient and/or other authorized individual, such as prescriber or caregiver.”

---


Currently, CMS guidance on when a CMR may be completed with a beneficiary’s provider does not provide enough clarity on what can and cannot be done, subjecting plan sponsors to differing interpretations. In order to ensure plan sponsors are compliant with MTM program requirements and successfully achieve the intent of identifying and resolving medication related problems, AMCP identified areas when the prescriber could be the recipient of the CMR. The areas identified below have been reviewed by members of the MTMAG and should be considered as an important starting point when considering ways to improve CMR delivery.

Start with the beneficiary: AMCP believes that CMR should be conducted directly with the beneficiary when possible. A good faith effort to complete the CMR with the beneficiary should include several attempts to contact the beneficiary by several means, such as by phone, in writing, or in some cases electronically.

Recognize potential barriers: There are several barriers which may prevent the beneficiary from directly participating in the CMR, and therefore, the prescriber should be permitted to participate on their behalf. The barriers include, but are not limited to:

- Access to services: Beneficiaries may not have access to an MTM provider or technology to connect with MTM providers.
- Health literacy: Due to the complexities of the healthcare system or the complexities of managing chronic illness, beneficiaries might not understand the services being offered or may prefer the service be delivered to their provider on their behalf.
- Preferred language: Language barriers may make it difficult for beneficiaries to receive the full benefit of the CMR. While translation services are widely available, they may not allow for a fully interactive consultation.
- Behavioral Health: Concomitant behavioral health issues may complicate the treatment of physical illness, coordination of care and ability to participate in the services.

Documenting services: The documentation of services should include details regarding the good faith effort to reach the beneficiary, the inability of the beneficiary to participate in the CMR and the name and relation of the authorized individual who participated in the completion of the CMR on behalf of the beneficiary. In addition, documentation should include all coordination of care efforts required to obtain optimal treatment outcomes. This should also include engagement with the necessary members of the beneficiary’s care team including the pharmacist.

AMCP supports the value of the CMR and therefore offers the solutions described above regarding CMR completion with a beneficiary’s prescriber. AMCP encourages CMS to build these recommendations into future Part D proposals or Health Plan Management System (HPMS) releases.
D. Part D Mail Order Auto-Ship Modifications

CMS Proposal
CMS is proposing to modify its Part D mail order auto-ship policy to permit PDPs to offer an opt-in voluntary auto-ship program for refills of established therapy.

AMCP Response
AMCP supports use of mail order pharmacy as a tool used by PDPs to increase patient safety in the delivery of medications, offer convenience to patients who choose the service, and to maintain the affordability of the prescription drug benefit. Therefore, AMCP supports CMS’s proposal to allow PDP plans the option to offer an opt-in auto-ship program for refills of established therapy as long as flexibilities for PDPs who choose to participate in the program are maintained.

Conclusion

AMCP appreciates your consideration of the concerns outlined above and looks forward to continuing work on these issues with CMS. If you have any questions regarding AMCP’s comments or would like further information, please contact me at 703-684-2600 or scantrell@amcp.org.

Sincerely,

Susan A. Cantrell, RPh, CAE
Chief Executive Officer

---

Findings from a National Survey of Medicare Beneficiary Perspectives on the Medicare Part D Medication Therapy Management Standardized Format

Nicole J. Brandt, PharmD, MBA, BCGP; Catherine E. Cooke, PharmD, BCPS, PAHM; Kriti Sharma, MD, MPH; Joshua Chou, PharmD; Mary Jo Carden, RPh, JD; Patty Kumbera, RPh; and Karen Pellegrin, PhD, MBA

ABSTRACT

BACKGROUND: The Medication Therapy Management (MTM) Program Standardized Format (SF) is a written summary of a comprehensive medication review (CMR) that must be provided to Medicare Part D beneficiaries. Concerns have been raised regarding the number of pages of the SF, mailing costs, the static nature of the document, and the lack of integration into beneficiaries’ electronic health records. To date, limited research exists on beneficiaries’ perceptions of the SF.

OBJECTIVE: To evaluate the perspectives of beneficiaries regarding the utility of the SF to inform potential modifications for optimal use.

METHODS: An online survey, designed based on the standard approach to measuring patient satisfaction with health service attributes and previous qualitative research, was distributed through Medicare Part D plans to beneficiaries who had received a CMR in the past year. Survey distribution began July 1, 2018, and data collection ended on October 31, 2018. Descriptive statistics are reported for demographic information; health status; perceived value and helpfulness of the SF and its 3 components (cover letter, medication action plan [MAP], personal medication list [PML]); updates to the SF; alternate formatting; and integration of the SF into health records.

RESULTS: A total of 9,975 surveys were sent electronically by 4 Medicare Part D plans to beneficiaries who had received a CMR in the past year. Of the 434 unduplicated survey respondents (response rate of 4.3%), 58.5% were aged 65 to 84 years; 60% identified themselves as white; and 49.1% had at least a college education. The most commonly reported comorbidities were diabetes (50.5%) and high cholesterol (43.1%), with 10.7% of respondents rating their health as “very good” or “excellent” and 27.4% choosing “poor” or “fair.” Beneficiaries rated how well the SF helped improve different aspects of their medication management (e.g., solving medication-related problems, keeping track of medications, correctly using medications, and understanding why medications are being taken), with 40.8%-44.9% choosing “very good” to “excellent” for each aspect. Helpful sections included “What we talked about” and “What I need to do” for the MAP, and medication name, strength, dosage form, and “How and why I use the medication.”

CONCLUSIONS: Fewer than half of the respondents perceived the SF as very good or excellent in helping them to manage their medications. This national survey provides Medicare beneficiary-focused evidence that more work is needed to improve the usability and portability of the SF. This can be achieved by allowing flexibility in the design of the SF, while including essential elements.

What is already known about this subject

- Medicare beneficiaries find the medication therapy management comprehensive medication review service valuable, yet the Standardized Format (SF) is not “memorable.”
- There is limited evidence about which aspects of the SF are valuable to Medicare beneficiaries and how the SF could be improved.

What this study adds

- This study found that only 40.8%-44.9% of participants rated the SF as “very good” or “excellent” in helping to improve their medication management.
- Within the SF, beneficiaries perceived the medication action plan (MAP) to be less useful than the personal medication list (PML), with 48.6% not writing in any information in the fill-in sections of the MAP.
- Study results showed that 44.7% of participants reported that they updated their PMLs and noted the most useful sections to be medication name, strength, dosage form, and “How and why I use the medication.”

In 2006, the Centers for Medicare & Medicaid Services (CMS) began offering a prescription drug benefit known as Part D to Medicare beneficiaries. In addition to managing the coverage of specified medications, participating sponsors in the Part D program must provide eligible Medicare beneficiaries with access to medication therapy management (MTM) services. According to the requirements for MTM programs under 42 CFR section 423.153(d) of the Medicare Prescription Drug Benefit Manual, a Part D sponsor must have established an MTM program that (a) ensures optimum therapeutic outcomes for targeted beneficiaries through improved medication use, (b) reduces the risk of adverse events, (c) is developed in coordination with licensed and practicing pharmacists and physicians, (d) describes the resources and time required to implement the program and establishes the fees for MTM providers, and (e) may be furnished by pharmacists or other qualified providers.1
One part of the MTM program is the comprehensive medication review (CMR), an interactive session with the beneficiary and qualified MTM provider where medications are reviewed, drug therapy problems are identified, and a plan for resolution is developed. The CMR must be delivered face to face or using telehealth technologies by a licensed pharmacist or other qualified provider, with a written medication review and action plan and input from the prescriber as necessary and practical. Since January 1, 2013, all beneficiaries receiving a CMR were required to receive a written summary of the encounter using the MTM Standardized Format (SF). The goal of this requirement was to advance consistency in the CMR service by providing a template of expected content.

Despite this requirement, barriers such as integration of the SF into electronic medical records and its lack of portability have decreased the potential utility of the CMR. Although there has been increased provider demand for electronic access to medication history and increased electronic exchange of health information among providers, the SF remains separate from the electronic medical record.

Beneficiaries have shared their perspectives on portability with CMS. In 2015, a survey of Medicare beneficiaries who had received a CMR found that one third could not recall receiving an SF, and 28% of those who remembered receiving one stated that they preferred a shorter personal medication list (PML) when they are taking a large number of medications. The utility of a long PML was examined in another survey of 9 Medicare beneficiaries who had also received a CMR. In the survey, 67% of beneficiaries noted that they personally created a separate, smaller handwritten list of medications for reference, presumably because the PML was not meeting their needs.

Other stakeholders have also raised concerns about the SF. Sharing the perspective of those implementing the SF requirement, the Academy of Managed Care Pharmacy (AMCP) noted that the typical SF is “10+ pages and costs an average of $1.39 to mail to the beneficiary.” Furthermore, Snyder et al. (2018) noted that pharmacists and pharmacy staff at 3 of 4 MTM practices reported dissatisfaction with the SF, noting that it was cumbersome and overwhelming for patients.

Because there is limited beneficiary-centered evidence about the SF, the objectives of this study were to understand beneficiary perceptions regarding the Medicare Part D MTM SF and to evaluate the utility of the SF to inform potential modifications for optimal use.

Methods

Study Design and Data Collection

The survey design was based on the standard approach for measuring patient satisfaction with health service attributes, as well as results obtained from previous research. In this approach, survey items reflect specific features of the episode of care, which, in our case, were the various aspects of the structure of the SF from the most recent CMR. Where appropriate, the response format of “excellent,” “very good,” “good,” “fair,” and “poor” was used rather than “very satisfied” to “very dissatisfied” because the former has been found to produce better psychometric properties. Global satisfaction items were also used to determine if any specific items were unrelated, indicating that specific feature was not likely a critical component of satisfaction with the overall episode of care, and which specific items were most strongly correlated, indicating those were likely the most critical components of satisfaction with the overall episode and, thus, priorities for improvement.

The emergent themes from the qualitative work included usefulness of certain SF sections, such as names of medications and how the patient should take them, and suggestions for additional sections, such as drug interactions, cheaper alternatives, and a priority listing of drugs. Another key theme was the suggestion for alternative methods or formats of delivery and more frequent updates. These themes were used to construct survey questions with multiple choices in 4 key focus areas: (1) overall value of the SF, (2) content and usability of the SF and its different sections, (3) delivery methods and updates, and (4) portability and sharing of the SF.

The survey was pilot tested based on the recommendations from a convenience sample of Medicare beneficiaries (n = 10) and selected committee members of the AMCP Advisory Group who had been involved with MTM research and survey design. Testers were asked to comment on the flow, clarity, and time to complete the survey. The wording, content, and duration of the survey were revised. Another round of testing with Medicare beneficiaries (n = 5) and members of the MTM research and survey design team accepted the revised survey, noting that it took approximately 20 minutes to complete.

The final survey was a structured questionnaire with 42 multiple-choice questions that covered the value and perception of the SF components (i.e., cover letter, MAP [medication action plan], and PML); the utility of individual sections within each component; the delivery of the SF; updates to the SF; and integration with health records (see Appendix, available in online article). There were 8 questions related to utility, 4 questions on use-based rating of the SF, 12 questions on the 3 components of the SF, and 3 questions on each component on the delivery and overall rating of the document. Most questions were perception based and had the potential responses of “yes,” “no,” or “not sure.” For the rating questions, the participants could choose 1 of 5 options: “poor,” “fair,” “good,” “very good,” and “excellent.” Deidentified demographic information was also collected. Participants were not asked to provide any information about their Medicare Part D plan.

Medicare Part D prescription drug plans and Medicare Advantage prescription drug plans that had representatives serving in the AMCP MTM advisory group, who were able
Findings from a National Survey of Medicare Beneficiary Perspectives on the Medicare Part D Medication Therapy Management Standardized Format

To participate in this research, distributed the surveys electronically to beneficiaries’ email addresses of record. Plans distributed the electronic link to the survey using SurveyMonkey to a sample of Medicare beneficiaries who had received a CMR in the past year. Survey distribution began on July 1, 2018, and data collection ended on October 31, 2018. There were no incentives offered; some plans sent reminder emails. Additionally, on the landing page before entering the survey, participants were directed to call the University of Maryland research team if assistance with completing the survey was desired.

Data Analysis
The descriptive analysis included all unduplicated surveys in the counts, irrespective of the completeness or recollection of receiving the SF. Duplicated surveys were identified by the Internet protocol address of the electronic survey submission, and in all instances, the most complete (i.e., the survey with the highest number of answered questions) survey response was retained for inclusion in the analysis. Nonresponders (i.e., participants who skipped 1 or more questions) were included in the denominator and also described as a separate category (“Did not respond/Skipped”) for each question. Counts and percentages were reported for demographic and clinical information (i.e., age, race, gender, ZIP code, education, comorbidities, number of medications) and self-reported health status. Using participant-reported ZIP codes, the participant’s geographic state was identified and then categorized into geographic regions as delineated by the U.S. Census Bureau. Counts and percentages are also reported for the perceived value and helpfulness of the SF and its 3 components (cover letter, MAP, and PML), along with beneficiaries’ opinions on updates to the SF, alternate formatting of the SF, and integration of the SF with health records. Correlation analyses were conducted to assess the relationship between ratings of

| TABLE 1 Demographics and Health Status of Survey Participants (N=434) |
| Baseline Characteristics | n (% ) |
| Age |  |
| < 65 years | 45 (10.37) |
| 65-74 years | 164 (37.79) |
| 75-84 years | 90 (20.74) |
| > 85 years | 13 (3.00) |
| Prefer not to say | 3 (0.69) |
| Did not respond | 118 (27.42) |
| Ethnicity |  |
| Black/African American | 12 (2.76) |
| White | 260 (59.91) |
| Hispanic or Latino | 13 (3.00) |
| Native Hawaiian or Other Pacific Islander | 0 (0.00) |
| Asian | 10 (2.30) |
| American Indian or Alaska Native | 2 (0.46) |
| Other | 4 (0.92) |
| Prefer not to say | 18 (4.15) |
| Did not respond | 117 (26.96) |
| Gender |  |
| Female | 155 (35.71) |
| Male | 159 (36.64) |
| Prefer not to say | 2 (0.46) |
| Did not respond | 118 (27.19) |
| Highest education completed |  |
| Primary school | 2 (0.46) |
| Some high school, no diploma | 6 (1.38) |
| High school diploma (or GED) | 82 (18.89) |
| College or higher | 213 (49.08) |
| Prefer not to say | 12 (2.76) |
| Did not respond | 119 (27.42) |
| Geographic region |  |
| Northeast | 29 (6.78) |
| Midwest | 59 (13.59) |

GED = general equivalency diploma.
Findings from a National Survey of Medicare Beneficiary Perspectives on the Medicare Part D Medication Therapy Management Standardized Format

Results

From July 1, 2018, through October 31, 2018, 434 unduplicated surveys were received, resulting in a survey response of 4.3%. The completion rate for the 434 surveys was 71%.

Demographic Information and Health Status

Of the 434 electronic survey respondents, which included beneficiaries or their caregivers (n = 23), 37.8% were aged 65-74 years; 60% were white; and 49.1% had at least a college education (Table 1). The most commonly reported comorbidities were diabetes (50.5%) and high cholesterol (43.1%), with 10.7% rating their health as very good or excellent and 27.4% choosing poor or fair. About one fourth of respondents did not provide an answer for every question in this section, which may be partially explained by the fact that these questions were at the end of the survey.

Beneficiaries’ Self-Reported Information on Medication Reviews

The CMR had been conducted via telephone for 86.6% of respondents and completed by a pharmacist in 68.7% of surveys (Table 2). More than half of respondents had their last CMR within the past 3 months, but approximately 1 of every 5 (21.4%) could not recall when they had their last CMR. Although 75.4% noted they received an SF after their review, 11.8% said they had not received one, and another 11.1% were not sure. A majority of respondents (60.8%) kept their SFs. In terms of repeated use of the SF, 44.9% looked at it sometimes; 6.5% looked at it often; and 37.6% did not look at it at all.

There was a high degree of correlation between 7 questions evaluating the usefulness of the SF and the overall rating of the MTM service. There was a significant correlation between overall rating of the medication review and 4 questions based on various uses of the SF, that is, help in understanding the medications, using them correctly, tracking and solving any potential medication-related problems (r ≥ 0.70, P < 0.001). There was also a significant correlation (r ≥ 0.50, P < 0.001) between 3 questions on usefulness of the MAP and overall rating of the medication review. There was no significant correlation between the overall rating of the service and demographic information (i.e., age, gender, or education level) or the number of medications.

Ratings of the SF and Value of the MTM Services

Using “poor,” “fair,” “good,” “very good,” or “excellent,” survey respondents were asked to rate how well the SF helped them with managing their medications, such as providing a better understanding of the medications, keeping track of the medications, correct use of medications, and solving problems related to medications (r ≥ 0.70, P < 0.001). There was also a significant correlation (r ≥ 0.50, P < 0.001) between 3 questions on usefulness of the MAP and overall rating of the medication review. There was no significant correlation between the overall rating of the service and demographic information (i.e., age, gender, or education level) or the number of medications.

<table>
<thead>
<tr>
<th>TABLE 2</th>
<th>Delivery of the Comprehensive Medication Review and Use of the Standardized Format (N=434)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Findings</td>
<td>n (%)</td>
</tr>
<tr>
<td>CMR setting</td>
<td></td>
</tr>
<tr>
<td>In person</td>
<td>36 (8.29)</td>
</tr>
<tr>
<td>Over the phone</td>
<td>376 (86.64)</td>
</tr>
<tr>
<td>Telehealth videoconference</td>
<td>2 (0.46)</td>
</tr>
<tr>
<td>Do not recall</td>
<td>17 (3.92)</td>
</tr>
<tr>
<td>Did not respond</td>
<td>3 (0.69)</td>
</tr>
<tr>
<td>Provider completing medication review</td>
<td></td>
</tr>
<tr>
<td>Pharmacist</td>
<td>298 (68.66)</td>
</tr>
<tr>
<td>Physician</td>
<td>12 (2.76)</td>
</tr>
<tr>
<td>Nurse</td>
<td>25 (5.76)</td>
</tr>
<tr>
<td>Other</td>
<td>14 (3.23)</td>
</tr>
<tr>
<td>Do not recall</td>
<td>80 (18.43)</td>
</tr>
<tr>
<td>Did not respond</td>
<td>65 (1.55)</td>
</tr>
<tr>
<td>Time of last CMR</td>
<td></td>
</tr>
<tr>
<td>Within the past month</td>
<td>111 (25.58)</td>
</tr>
<tr>
<td>Within the past 3 months</td>
<td>123 (28.34)</td>
</tr>
<tr>
<td>Within the past 6 months</td>
<td>30 (6.91)</td>
</tr>
<tr>
<td>Within the past year</td>
<td>73 (16.82)</td>
</tr>
<tr>
<td>Do not recall</td>
<td>93 (21.43)</td>
</tr>
<tr>
<td>Did not respond</td>
<td>4 (0.92)</td>
</tr>
<tr>
<td>Receipt of summary after the CMR</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>327 (75.35)</td>
</tr>
<tr>
<td>No</td>
<td>51 (11.75)</td>
</tr>
<tr>
<td>Not sure</td>
<td>48 (11.06)</td>
</tr>
<tr>
<td>Did not respond</td>
<td>8 (1.84)</td>
</tr>
<tr>
<td>If you received a medication review summary, did you keep it?</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>264 (60.83)</td>
</tr>
<tr>
<td>No</td>
<td>60 (13.82)</td>
</tr>
<tr>
<td>Not sure</td>
<td>75 (17.28)</td>
</tr>
<tr>
<td>Did not respond</td>
<td>35 (8.06)</td>
</tr>
<tr>
<td>If you kept your summary, how often do you look at it?</td>
<td></td>
</tr>
<tr>
<td>Often</td>
<td>28 (6.45)</td>
</tr>
<tr>
<td>Sometimes</td>
<td>195 (44.93)</td>
</tr>
<tr>
<td>Not at all</td>
<td>163 (37.56)</td>
</tr>
<tr>
<td>Did not respond</td>
<td>48 (11.06)</td>
</tr>
</tbody>
</table>

CMR = comprehensive medication review
Respondents rated MTM service “very good” to “excellent” (41.7%) and 31.3% “good” to “poor.” However, 63% of respondents would recommend the MTM service to friends or relatives who needed help with their medications.

Opinions on Individual Sections of the SF
Most respondents (52.5%) found the cover letter helpful, and 35.3% preferred that the cover letter be kept in the SF. Between 47.5% and 50.5% found the MAP and the sections “What we talked about” and “What I need to do” helpful. However, 48.6% reported they did not write anything in the fill-in sections of the MAP. Furthermore, only 35.5% of respondents preferred keeping the MAP in the SF, whereas 31.8% had no preference, and another 20.1% skipped the question or did not respond.

The PML garnered more long-term utility, with 44.7% of the respondents reporting that they update their PMLs, and 14.3% reporting that they do not. The most useful sections of the PML were medication name, strength, dosage form, and “How and why I use the medication” (Figure 2). One in 4 (25.8%) preferred a vertical page format, and 22.6% preferred a horizontal page format; approximately half had no preference or skipped the question.

Participants expressed interest in adding information to the PML on common drug interactions (39.6%), side effects (40.3%), and special instructions (40.3%). Furthermore, 34.8% requested information about alternative medications in the same class that could be cheaper.

Delivery and Integration
When asked for their opinion regarding the integration of the medication summary into their health records, over half (55.3%) of respondents were in favor, while 9.4% were against it, and 9.9% were not sure (Table 3). In addition, 42.9% felt that an electronic copy of the SF would be helpful.

The majority (54.6%) of respondents reported that they would use a wallet card if available and would prefer it be filled out with their information before receiving it (62.4%). When they were asked about what information they would like included on the wallet card, the most popular responses were prescription medications (64.1%), followed by medical conditions (50.2%) and alerts for emergency personnel, such as “patient is receiving blood thinners” (47.9%).

Finally, 30% of respondents brought their SFs to their doctors, and 39.6% did not; 26% gave copies of their SFs to their relatives, and 46.1% did not.

Discussion
If requirements for Medicare eligibility remain the same, the Medicare population is expected to increase from 54 million in 2015 to more than 80 million beneficiaries in 2030. This increased population will likely result in an increased number of beneficiaries receiving the SF as part of the CMR service. There is growing importance in understanding the Medicare beneficiary perspective on the value and utility of the SF, as well as the MTM service, to improve medication-related outcomes. The findings from this study, the largest study to date to gather beneficiary perceptions of the Medicare Part D MTM SF, can provide insight into modernizing the MTM program. Because there were significant correlations between overall rating and recommendation for the MTM service with key questions from the survey, these results suggest that the SF is a meaningful part of the medication review service and that improving sections of the SF may improve overall ratings of the MTM service. While 63% of the 434 respondents in this survey would recommend the MTM service to their friends or relatives if they needed help with their medications, only between 40% and 45% rated the SF as very good or excellent.
Findings from a National Survey of Medicare Beneficiary Perspectives on the Medicare Part D Medication Therapy Management Standardized Format

All components of the SF contained essential elements, but Medicare beneficiaries shared their perspectives on how to improve the SF. Based on the results of this study, there are several recommendations to address beneficiary needs for each component of the SF:

- **Cover Letter:** No modifications suggested.
- **Medication Action Plan:** Remove the sections “What I did and when I did it”; “My follow-up plan”; and “Questions I want to ask,” that is, all sections that require the beneficiary to fill them out.
- **Personal Medication List:** Remove the sections “Date I started” and “Date I stopped and why.” Further evaluate the Prescriber field. Create beneficiary-friendly mechanisms for more timely updates (e.g., health record portal).

However, these recommendations appear to make cuts or additions to the existing SF that may be short sighted. This is not the intent of these recommendations, but a beginning to identify helpful data elements that are meaningful to beneficiaries and facilitate integration. Layout and design of health information are important; thus, we included such items as part of our approach to measuring specific features of SF. Beneficiaries and health care providers support the integration of the SF into existing electronic health and medication records, yet there is no consensus on what the SF should “look like.” Rather, action should be taken to have consistent domains (i.e., data elements) that can be adapted to meet the needs of the beneficiary and his or her caregiver. For example, these changes would allow a modifiable printout (e.g., wallet card) for beneficiary and/or caregiver access, such as the current program available at eMedicare. Transforming the SF into interoperable elements meaningful to the beneficiary would help address integration and improve goal attainment of increased medication effectiveness and safety for Medicare Part D beneficiaries. However, there were 9.4% of Medicare beneficiaries who did not want this information integrated into their medical records. These findings are consistent with previous research on consumer attitudes regarding health information exchange. Although a majority support the use of health information exchange owing to perceived benefits, there are those who do not, likely due to privacy/security concerns. Furthermore, engaging Medicare

---

**FIGURE 2** Opinions on the Usefulness of PML Sections

<table>
<thead>
<tr>
<th>Sections of the PML</th>
<th>Percentage of respondents who chose section as being useful</th>
</tr>
</thead>
<tbody>
<tr>
<td>Why I stopped it</td>
<td>12.7</td>
</tr>
<tr>
<td>Date stopped it</td>
<td>12.7</td>
</tr>
<tr>
<td>Date started it</td>
<td>20.5</td>
</tr>
<tr>
<td>Prescriber</td>
<td>23.7</td>
</tr>
<tr>
<td>Why use it</td>
<td>42.9</td>
</tr>
<tr>
<td>How I use it</td>
<td>38.2</td>
</tr>
<tr>
<td>Dosage form (i.e., tablet, capsule, topical solution)</td>
<td>38.2</td>
</tr>
<tr>
<td>Medication strength</td>
<td>41.5</td>
</tr>
<tr>
<td>Medication name</td>
<td>51.4</td>
</tr>
</tbody>
</table>

PML = personal medication list.
Findings from a National Survey of Medicare Beneficiary Perspectives on the Medicare Part D Medication Therapy Management Standardized Format

Table 3: Opinions on Integration and Format of the Standardized Format

<table>
<thead>
<tr>
<th>Questions on Integration and Format (N=434)</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Your opinion on the length of the summary</strong></td>
<td></td>
</tr>
<tr>
<td>Too long</td>
<td>47 (10.83)</td>
</tr>
<tr>
<td>Too short</td>
<td>2 (0.46)</td>
</tr>
<tr>
<td>Just the right length</td>
<td>215 (49.54)</td>
</tr>
<tr>
<td>Not sure</td>
<td>58 (13.36)</td>
</tr>
<tr>
<td>Skipped/did not respond</td>
<td>112 (25.81)</td>
</tr>
<tr>
<td><strong>Would you use a wallet card, if one was provided?</strong></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>237 (54.61)</td>
</tr>
<tr>
<td>No</td>
<td>51 (11.75)</td>
</tr>
<tr>
<td>Unsure</td>
<td>46 (10.60)</td>
</tr>
<tr>
<td>Skipped/did not respond</td>
<td>100 (23.04)</td>
</tr>
<tr>
<td><strong>What information would you like to be included on the wallet card?</strong></td>
<td></td>
</tr>
<tr>
<td>Prescription medications</td>
<td>278 (64.06)</td>
</tr>
<tr>
<td>Alert medications for emergency personnel (e.g., use of blood thinner)</td>
<td>208 (47.93)</td>
</tr>
<tr>
<td>Over-the-counter medications</td>
<td>110 (25.35)</td>
</tr>
<tr>
<td>Allergies</td>
<td>179 (41.24)</td>
</tr>
<tr>
<td>Medical conditions</td>
<td>218 (50.23)</td>
</tr>
<tr>
<td>Other (please specify)</td>
<td>18 (4.15)</td>
</tr>
<tr>
<td>Skipped/did not respond</td>
<td>119 (27.42)</td>
</tr>
<tr>
<td><strong>Do you bring your medication review summary to your doctor visit?</strong></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>131 (30.18)</td>
</tr>
<tr>
<td>No</td>
<td>172 (39.63)</td>
</tr>
<tr>
<td>Not sure</td>
<td>22 (5.07)</td>
</tr>
<tr>
<td>Skipped/did not respond</td>
<td>109 (25.12)</td>
</tr>
<tr>
<td><strong>Do you give copies of your medication summary to your relatives?</strong></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>113 (26.04)</td>
</tr>
<tr>
<td>No</td>
<td>200 (46.08)</td>
</tr>
<tr>
<td>Not sure</td>
<td>10 (2.30)</td>
</tr>
<tr>
<td>Skipped/did not respond</td>
<td>111 (25.58)</td>
</tr>
</tbody>
</table>

The primary limitation of this study is the response rate of 4.3%, which is lower than the historic rate for the Medicare prescription drug plan Consumer Assessment of Healthcare Providers and Systems survey.18 Web surveys such as ours are more efficient but typically have lower response rates compared with mailed surveys.19 As of 2016, approximately 65% of Medicare beneficiaries indicated that they use the Internet daily or almost daily,20 but it is unclear how many surveys reached the intended recipients, owing to the inaccuracy of email addresses on record, or were opened, owing to incompatibility with technology used to access emails.

Despite the relatively low response, the race, age, and other demographics presented are reflective of the greater Medicare beneficiary population. For instance, 60% of our respondents were white, and according to the Medicare Payment Advisory Committee report, 74% of beneficiaries are white. Further, 40% of our respondents had a college or postgraduate education, whereas 19% had a high school diploma only, compared with national estimates of 54% and 28% respectively.21 Additional research is needed to confirm these findings.

Although recall bias is a concern with surveys, this aspect was minimized by limiting those eligible for inclusion to those who had had a CMR within the past year. Participating Part D plans were asked to sample from those beneficiaries who had a CMR within the past year. Future studies should continue to engage the Medicare beneficiary in codesign of health care services and format of medication information.

### Conclusions

Fewer than half of the Medicare beneficiary respondents perceived the SF as very good or excellent with helping to manage their medications. This national survey, the largest to date, provides Medicare beneficiary-focused evidence that more work needs to be done to improve the usability and portability of the SF. These aspects can be achieved by allowing flexibility in the design of the SF while requiring essential elements. MTM programs need to integrate the SF into health records and allow a modifiable printout available (e.g., wallet card and other digital, user-friendly formats).

### Authors

NICOLE J. BRANDT, PharmD, MBA, BCGP; CATHERINE E. COOKE, PharmD, BCPP, PAHM; KRITI SHARMA, MD, MPH; and JOSHUA CHOU, PharmD, University of Maryland School of Pharmacy, Baltimore. MARY JO CARDEN, RPh, JD, and PATTY KUMBERA, RPh, Academy ofManaged Care Pharmacy, Alexandria, Virginia. KAREN PELLEGRIN, PhD, MBA, University of Hawai‘i at Hilo.

AUTHOR CORRESPONDENCE: Nicole J. Brandt, PharmD, MBA, BCGP, University of Maryland School of Pharmacy, The Lamy Center, 220 Arch St., 12th Fl., Baltimore, MD 21201. Tel.: 410.706.1491; E-mail: nbrandt@rx.umd.edu.

### DISCLOSURES

This study was funded by the Academy of Managed Care Pharmacy (AMCP), which provided a grant to the University of Maryland School of Pharmacy to conduct this study. Carden and Kumbera are AMCP employees. Brandt reports a grant from IMPAQ and consulting fees from Rand, outside of this study. Pellegrin is a member of the AMCP MTM Advisory Board. The other authors have nothing to disclose.

### REFERENCES

Findings from a National Survey of Medicare Beneficiary Perspectives on the Medicare Part D Medication Therapy Management Standardized Format


Greetings! You or someone you care for recently had a medication review by a pharmacist or other provider as part of the Medicare Part D prescription drug plan. After reviewing all of your medications and how to take them, you should have received a summary document of that review. This medication review summary includes: a **cover letter**, **personal medication list**, and **medication action plan**. We want to learn which parts of the summary are most useful to you and what role you feel the summary should play in your care.

If you have your medication review summary handy, you may find it helpful as a reference while you complete this survey. Here is an example of the cover letter:

---

01/01/2016

Dear Mr. John Doe:

Thank you for talking with me on 12/28/2015 about your health and medications. Medicare’s MTM (Medication Therapy Management) program helps you make sure that your medications are working. Along with this letter are an action plan (Medication Action Plan) and a medication list (Personal Medication List). **The action plan has steps you should take to help you get the best results from your medications. The medication list will help you keep track of your medications and how to use them the right way.**

- Have your action plan and medication list with you when you talk with your doctors, pharmacists, and other health care providers.
- Ask your doctors, pharmacists, and other healthcare providers to update them at every visit.

---

This survey should take no more than 25 minutes to complete. All survey responses are anonymous. Individual responses will not be made available to your health insurance provider. This survey has been approved by the Institutional Review Board at the University of Maryland Baltimore. If you have additional questions, please contact the Principal Investigator, Dr. Nicole Brandt, at nbrandt@rx.umaryland.edu or 410-706-1491. Thank you for your time and feedback completing the survey.
Findings from a National Survey of Medicare Beneficiary Perspectives on the Medicare Part D Medication Therapy Management Standardized Format

APPENDIX Medication Review Summary Satisfaction Survey (continued)

Please tell us about your medication review.

We would like to know more about the medication review you had with a pharmacist or other healthcare provider.

1. Who had a recent medication review?
   - Me (the Medicare Part D member)
   - Me (I also had a caregiver there to help)
   - Caregiver on behalf of a member (I am taking the survey as the caregiver)
   - Other (please specify)

2. How did you have your medication review?
   - In person
   - Over the phone
   - Telehealth videoconference
   - Do not recall

3. Which type of provider completed your medication review?
   - A pharmacist
   - A physician
   - A nurse
   - Do not recall
   - Other (please specify)
APPENDIX

Medication Review Summary Satisfaction Survey (continued)

4. When was your last medication review?
   - Within the past month
   - Within the past 3 months
   - Within the past 6 months
   - Within the past year
   - Do not recall

Please tell us more about the medication review summary overall.

Note: You may find it helpful to have your medication review summary on hand as you complete this survey. You can refer to your summary when answering any of the questions.

5. Did you receive a medication review summary?
   - Yes
   - No
   - Not sure

6. If you received a medication review summary, did you keep it?
   - Yes
   - No
   - Not sure

7. If you kept your summary, how often do you look at it?
   - Often
   - Sometimes
   - Not at all
Appendix: Medication Review Summary Satisfaction Survey (continued)

Please tell us more about the overall value of your medication review summary.

We would like you to rate how well the medication review summary has helped you in the following areas --

8 How well has the medication review summary helped you to understand why you are taking your medications?
   - Poor
   - Fair
   - Good
   - Very Good
   - Excellent

9 How well has the medication review summary helped you to correctly take your medications (for example: at the correct time, with or without food)
   - Poor
   - Fair
   - Good
   - Very Good
   - Excellent

10 How well has the medication review summary helped you to keep track of what medications you are taking?
    - Poor
    - Fair
    - Good
    - Very Good
    - Excellent
APPENDIX  Medication Review Summary Satisfaction Survey (continued)

11. How well has the medication review summary helped you to solve any medication problems found during the medication review (for example: drug-drug interactions, side effects)?
   - Poor
   - Fair
   - Good
   - Very Good
   - Excellent

Please give us feedback on the medication review summary content and usefulness

Questions 12-13 will ask about the cover letter from the medication review summary. Example:

01/01/2016
Dear Mr. John Doe:

Thank you for talking with me on 12/28/2015 about your health and medications. Medicare’s MTM (Medication Therapy Management) program helps you make sure that your medications are working. Along with this letter are an action plan (Medication Action Plan) and a medication list (Personal Medication List). The action plan has steps you should take to help you get the best results from your medications. The medication list will help you keep track of your medications and how to use them the right way.

- Have your action plan and medication list with you when you talk with your doctors, pharmacists, and other health care providers.
- Ask your doctors, pharmacists, and other healthcare providers to update them at every visit.

12. Does the cover letter include helpful information?
   - Yes
   - No
   - Not sure
What is your preference about the cover letter?

- Keep the cover letter in the summary
- Make the cover letter shorter
- Include more information in the cover letter
- Remove the cover letter in the summary
- No preference

Please give us feedback on the medication summary content and usefulness

Questions 14-18 will ask about the medication action plan in the medication review summary.

Example:

MEDICATION ACTION PLAN FOR Joe Doe, DOB: 01/01/1941

This action plan will help you get the best results from your medications if you:

1. Read “What we talked about.”
2. Take the steps listed in the “What I need to do” boxes.
3. Fill in “What I did and when I did it.” 4. Fill in “My follow-up plan” and “Questions I want to ask.”

Have this action plan with you when you talk with your doctors, pharmacists, and other healthcare providers. Share this with your family or caregivers too.

DATE PREPARED: 01/01/2016

| What we talked about: |
| What I need to do: | What I did and when I did it: |

| My follow-up plan: |

| Questions I want to ask: |
Which section(s) of the medication action plan did you fill out?
Please select all that apply.

☐ "What I did and when I did it"
☐ "My follow-up plan"
☐ "Questions I want to ask"
☐ None
☐ Not sure

Do you find the “What we talked about” in the medication action plan helpful?

☐ Yes
☐ No
☐ Not sure

Do you find the "What I need to do" in the medication action plan helpful?

☐ Yes
☐ No
☐ Not sure

Do you find the medication action plan helpful overall?

☐ Yes
☐ No
☐ Not sure
18 What is your preference about the medication action plan?

- Keep the medication action plan in the summary
- Make the medication action plan shorter
- Include more information in the medication action plan
- Remove the medication action plan in the summary
- No preference

Please give us feedback on the medication review summary content and usefulness

Questions 19-22 will ask about the personal medication list in the medication review summary.

Example:

```
PERSONAL MEDICATION LIST FOR John Doe, DOB: 01/01/1941
(Continued)

| Medication: Metoprolol Succinate ER Oral Tablet Extended Release 24 Hour 25 MG |
| How I use it: Take one tablet by mouth every day |
| Why I use it: Heart Failure |
| Date I started using it: | Date I stopped using it: |
| Why I stopped using it: |

| Medication: Spironolactone Oral Tablet 25 MG |
| How I use it: Take one tablet by mouth every morning |
| Why I use it: Heart Failure |
| Date I started using it: | Date I stopped using it: |
| Why I stopped using it: |
```
What information currently included in the personal medication list do you find helpful?
Please select all that apply.

- [ ] Medication name
- [ ] Medication strength
- [ ] Dosage form (for example: tablet, capsule, topical solution)
- [ ] How I use it
- [ ] Why I use it
- [ ] Prescriber
- [ ] Date I started using it
- [ ] Date I stopped using it
- [ ] Why I stopped using it

What other information, if any, would you find helpful to have in the personal medication list?
Please select all that apply.

- [ ] Common drug interactions
- [ ] Common side effects
- [ ] Special instructions (for example: with or with food)
- [ ] Available alternatives -- other medications in the same drug class that may be cheaper
- [ ] Other (please specify)
How would you prefer to see the personal medication list presented in the medication review summary?

A) Horizontal

John Doe
DOB: 01/01/1941

Created: 01/01/1941
Prepared by: Jane Smith, PharmD

MY MEDICATION INFORMATION

Medications that I take (prescription, non-prescription, natural health products, homeopathic remedies)

<table>
<thead>
<tr>
<th>Medication</th>
<th>How I use it</th>
<th>Why I use it</th>
<th>Date I started using it</th>
<th>Date I stopped using it</th>
<th>Why I stopped using it</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metoprolol Succinate ER Oral Tablet Extended Release 24 Hour 25 mg</td>
<td>Take one tablet every day</td>
<td>Heart Failure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spironolactone Oral Tablet 25 mg</td>
<td>Take one tablet every morning</td>
<td>Heart Failure</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B) Vertical

PERSONAL MEDICATION LIST FOR John Doe, DOB: 01/01/1941
(Continued)

Medication: Metoprolol Succinate ER Oral Tablet Extended Release 24 Hour 25 MG
How I use it: Take one tablet every day
Why I use it: Heart Failure
Date I started using it: 
Date I stopped using it: 
Why I stopped using it:

Medication: Spironolactone Oral Tablet 25 MG
How I use it: Take one tablet every morning
Why I use it: Heart Failure
Date I started using it: 
Date I stopped using it: 
Why I stopped using it:

○ A horizontal format
○ A vertical format
○ No preference
What is your preference about the **personal medication list** overall?

- [ ] Keep the personal medication list in the summary
- [ ] Make the personal medication list shorter
- [ ] Include more information in the personal medication list
- [ ] Remove the personal medication list in the summary
- [ ] No preference
APPENDIX  Medication Review Summary Satisfaction Survey (continued)

Additional materials

Right now the medication review summary includes a cover letter, medication action plan, and personal medication list. We would like to know if there are other materials you would find helpful to manage your medications.

For example a wallet card:

<table>
<thead>
<tr>
<th>Name</th>
<th>OVER-THE-COUNTER MEDICATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone #</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Emergency Contact and Relationship</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Doctor's Name and Phone #</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PRESCRIPTION MEDICATIONS</strong></td>
<td></td>
</tr>
<tr>
<td>Include name and strength of each medication, what it is for, how much to take, and when.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

|  | OVER-THE-COUNTER MEDICATIONS |
|  |                              |

|  | OVER-THE-COUNTER MEDICATIONS |
|  |                              |

|  | OVER-THE-COUNTER MEDICATIONS |
|  |                              |

|  | OVER-THE-COUNTER MEDICATIONS |
|  |                              |

|  | OVER-THE-COUNTER MEDICATIONS |
|  |                              |

|  | OVER-THE-COUNTER MEDICATIONS |
|  |                              |

|  | OVER-THE-COUNTER MEDICATIONS |
|  |                              |

<table>
<thead>
<tr>
<th><strong>BLOOD THINNER</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>I take blood thinner medication</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name of Medication:</th>
<th>MEDICATION WALLET CARD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Take this card with you each time you go to the doctor, pharmacist or hospital.</td>
</tr>
</tbody>
</table>
APPENDIX  Medication Review Summary Satisfaction Survey (continued)

23. Would you use a wallet card if one was provided in your medication review summary?
   - Yes
   - No
   - Unsure

24. If you were provided with a wallet card, what information would you like to have included on the wallet card?
   Please select all that apply.
   - Prescription medications
   - Alert medications for emergency personnel (for example: use of blood thinner)
   - Over the counter medications
   - Allergies
   - Medical conditions
   - Other (please specify)

25. Would you prefer the wallet card already be filled out with your information and medications when you get it?
   - Yes
   - No
   - Not sure
Findings from a National Survey of Medicare Beneficiary Perspectives on the Medicare Part D Medication Therapy Management Standardized Format

APPENDIX  Medication Review Summary Satisfaction Survey (continued)

Please give us feedback on the how you use your medication review summary.

We would like to know more about who you share the summary with and what role you think these documents should play in your care.

26 Would having an electronic copy of your medication review summary (for example: through your email, health insurance secured website) be helpful to you?
- Yes
- No
- Not sure

27 Do you bring your medication review summary to your doctor visit?
- Yes
- No
- Not sure

28 Do you give copies of your medication summary to your relatives or caregiver?
- Yes
- No
- Not sure

29 Do you want your medication review summary to be part of your health record (for example: as part of your personal medical file, accessible by your health care providers)?
- Yes
- No
- Not sure
### Medication Review Summary Satisfaction Survey (continued)

#### 30. Do you update the Personal Medication List included in your summary (for example: when you get new prescriptions or your doctor changes the way you take your current medications)?
- [ ] Yes
- [ ] No
- [ ] Sometimes
- [ ] Not sure

Please provide us with your overall feedback about the medication review summary.

#### 31. Was your last medication review summary too long, too short, or just the right length?
- [ ] Too long
- [ ] Too short
- [ ] Just the right length
- [ ] Not sure

#### 32. Overall, how would you rate the medication review you got as part of your Medicare Part D plan (including the process of reviewing your medications and the documents you received from this review process)?
- [ ] Poor
- [ ] Fair
- [ ] Good
- [ ] Very Good
- [ ] Excellent
APPENDIX Medication Review Summary Satisfaction Survey (continued)

33 If a friend or family member needed help with their medications, would you recommend they complete a medication review?
- Yes, Definitely
- Yes, Probably
- No, Probably not
- No, Definitely not

34 What would you change about the medication review summary to help you understand and manage your medications better?

[Text Box]

Please tell us a little about yourself.

We would like to know some basic information about our survey participants. You are not required to provide responses in order to participate further in the survey.

35 What is your home zip code?

[Text Box]

36 What is your age?
- Less than 65
- 65-74
- 75-84
- 85 or older
- Prefer not to say
Findings from a National Survey of Medicare Beneficiary Perspectives on the Medicare Part D Medication Therapy Management Standardized Format

Findings from a National Survey of Medicare Beneficiary Perspectives on the Medicare Part D Medication Therapy Management Standardized Format

We would like to know some basic information about our survey participants. You are not required to provide responses in order to participate further in the survey.

Please tell us a little about yourself.

What is your home zip code?

What is your age?

Less than 65

65-74

75-84

85 or older

Prefer not to say

What is your gender?

Female

Male

Prefer not to say

Other (please specify)

What is your race/ethnicity?

Black or African American

White

Hispanic or Latino

Native Hawaiian or Other Pacific Islander

Asian

American Indian or Alaska Native

Prefer not to say

Other (please specify)

What is the highest level of school that you have completed?

Primary school

Some high school, but no diploma

High school diploma (or GED)

College or higher

Prefer not to say
APPENDIX  Medication Review Summary Satisfaction Survey (continued)

40. Please select which of the following conditions you have (as diagnosed by a healthcare provider):
   - [ ] Asthma
   - [ ] Chronic heart failure (CHF)
   - [ ] Chronic obstructive pulmonary disease (COPD)
   - [ ] Depression
   - [ ] Diabetes
   - [ ] High blood pressure (hypertension)
   - [ ] Heart problems
   - [ ] High cholesterol (dyslipidemia)
   - [ ] Irregular heart rate (atrial fibrillation)
   - [ ] Memory problems (dementia)
   - [ ] Osteoporosis
   - [ ] Rheumatoid arthritis
   - [ ] Other (please specify)

41. How many medications (including over-the-counter, prescriptions, herbals) do you currently take?

42. During the past 4 weeks, how would you rate your health in general?
   - [ ] Poor
   - [ ] Fair
   - [ ] Good
   - [ ] Very Good
   - [ ] Excellent

Thank you for taking the time to complete this survey.